The Experts below are selected from a list of 29643 Experts worldwide ranked by ideXlab platform
Meera Mahalingam - One of the best experts on this subject based on the ideXlab platform.
-
an immunohistochemical comparison of Cytokeratin 7 Cytokeratin 15 Cytokeratin 19 cam 5 2 carcinoembryonic antigen and nestin in differentiating porocarcinoma from squamous cell carcinoma
Human Pathology, 2012Co-Authors: Meera Mahalingam, Joanna E Richards, Alona Muzikansky, Angelica M Selim, Mai P. HoangAbstract:Summary The distinction of porocarcinoma from squamous cell carcinoma is clinically relevant but can often be a diagnostic dilemma. Current markers reported to be helpful in diagnosing porocarcinoma include carcinoembryonic antigen and Cytokeratin 7; however, their expression has been demonstrated in 30% to 80% and 13% to 22% of squamous cell carcinoma cases, respectively. In this study, we assessed immunohistochemical expression of Cytokeratin 7, Cytokeratin 15, Cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in 67 cases (39 porocarcinomas and 28 moderately differentiated squamous cell carcinomas) to determine their use as histologic adjuncts. Expression of carcinoembryonic antigen, Cytokeratin 19, Cytokeratin 7, CAM 5.2, Cytokeratin 15, and nestin was seen in 77%, 67%, 64%, 51%, 49%, and 13% of porocarcinomas, respectively; and in 57%, 18%, 26%, 32%, 30%, and 37% of squamous cell carcinomas, respectively. Of these, Cytokeratin 19 was the most specific (specificity, 82%) in detecting porocarcinomas, and carcinoembryonic antigen was the most sensitive (sensitivity, 77%). By χ 2 test, statistically significant P values ( P = .0003). In conclusion, we found Cytokeratin 19 to be a helpful marker in the distinction of porocarcinoma from squamous cell carcinoma, although a focal staining pattern can be seen in a third of cases. The diagnostic sensitivity and specificity appear to be significantly improved using a selected panel of immunohistochemical stains that include Cytokeratin 7, Cytokeratin 19, and nestin.
-
an immunohistochemical comparison of Cytokeratin 7 Cytokeratin 15 Cytokeratin 19 cam 5 2 carcinoembryonic antigen and nestin in differentiating porocarcinoma from squamous cell carcinoma
Human Pathology, 2012Co-Authors: Meera Mahalingam, Joanna E Richards, Alona Muzikansky, Angelica M Selim, Mai P. HoangAbstract:Summary The distinction of porocarcinoma from squamous cell carcinoma is clinically relevant but can often be a diagnostic dilemma. Current markers reported to be helpful in diagnosing porocarcinoma include carcinoembryonic antigen and Cytokeratin 7; however, their expression has been demonstrated in 30% to 80% and 13% to 22% of squamous cell carcinoma cases, respectively. In this study, we assessed immunohistochemical expression of Cytokeratin 7, Cytokeratin 15, Cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in 67 cases (39 porocarcinomas and 28 moderately differentiated squamous cell carcinomas) to determine their use as histologic adjuncts. Expression of carcinoembryonic antigen, Cytokeratin 19, Cytokeratin 7, CAM 5.2, Cytokeratin 15, and nestin was seen in 77%, 67%, 64%, 51%, 49%, and 13% of porocarcinomas, respectively; and in 57%, 18%, 26%, 32%, 30%, and 37% of squamous cell carcinomas, respectively. Of these, Cytokeratin 19 was the most specific (specificity, 82%) in detecting porocarcinomas, and carcinoembryonic antigen was the most sensitive (sensitivity, 77%). By χ 2 test, statistically significant P values ( P = .0003). In conclusion, we found Cytokeratin 19 to be a helpful marker in the distinction of porocarcinoma from squamous cell carcinoma, although a focal staining pattern can be seen in a third of cases. The diagnostic sensitivity and specificity appear to be significantly improved using a selected panel of immunohistochemical stains that include Cytokeratin 7, Cytokeratin 19, and nestin.
-
stem cell markers Cytokeratin 15 Cytokeratin 19 and p63 in in situ and invasive cutaneous epithelial lesions
Modern Pathology, 2011Co-Authors: Ossama Abbas, Joanna E Richards, Ron Yaar, Meera MahalingamAbstract:The inherent longetivity of stem cells causes them to be susceptible to multiple genetic hits. Thus, it is not surprising that stem cells are implicated in the etiopathogenesis of select cutaneous neoplasms. However, most studies to date are restricted to the use of a single marker (p63, Cytokeratin-15 or Cytokeratin-19) and do not appear to compare distribution of stem cell markers in a spectrum of cutaneous in situ versus invasive epithelial malignancies. In this study, we evaluate expression of Cytokeratin-15, Cytokeratin-19, and p63 in a series of primary cutaneous epithelial lesions that include actinic keratosis (n=29), squamous cell carcinoma in situ (n=30), bowenoid papulosis (n=15) and squamous cell carcinoma, well differentiated (n=29) in order to evaluate the role of stem cell marker expression in the grading and development of in situ and invasive malignancies. For Cytokeratin-15, expression was retained in actinic keratosis (38%), squamous cell carcinoma in situ (53%) and bowenoid papulosis (60%) but appeared to be lost in squamous cell carcinoma (3%) with statistically significant differences observed between groups that retained versus those that did not (P<0.05 for all three); for Cytokeratin-19, patchy yet basal expression was noted in actinic keratosis (21%), patchy and suprabasal expression was noted in squamous cell carcinoma in situ (37%), bowenoid papulosis (13%) and squamous cell carcinoma (24%) with no statistically significant differences between groups; for p63, expression was retained in actinic keratosis (90%), squamous cell carcinoma in situ (87%), bowenoid papulosis (60%) and squamous cell carcinoma (100%) with no statistically significant differences between groups. In summary, our findings expand the neoplasms which involve stem cells to include cutaneous epithelial malignancies. Differential localization of each of these markers argues in favor of stem cell heterogeneity.
Mai P. Hoang - One of the best experts on this subject based on the ideXlab platform.
-
an immunohistochemical comparison of Cytokeratin 7 Cytokeratin 15 Cytokeratin 19 cam 5 2 carcinoembryonic antigen and nestin in differentiating porocarcinoma from squamous cell carcinoma
Human Pathology, 2012Co-Authors: Meera Mahalingam, Joanna E Richards, Alona Muzikansky, Angelica M Selim, Mai P. HoangAbstract:Summary The distinction of porocarcinoma from squamous cell carcinoma is clinically relevant but can often be a diagnostic dilemma. Current markers reported to be helpful in diagnosing porocarcinoma include carcinoembryonic antigen and Cytokeratin 7; however, their expression has been demonstrated in 30% to 80% and 13% to 22% of squamous cell carcinoma cases, respectively. In this study, we assessed immunohistochemical expression of Cytokeratin 7, Cytokeratin 15, Cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in 67 cases (39 porocarcinomas and 28 moderately differentiated squamous cell carcinomas) to determine their use as histologic adjuncts. Expression of carcinoembryonic antigen, Cytokeratin 19, Cytokeratin 7, CAM 5.2, Cytokeratin 15, and nestin was seen in 77%, 67%, 64%, 51%, 49%, and 13% of porocarcinomas, respectively; and in 57%, 18%, 26%, 32%, 30%, and 37% of squamous cell carcinomas, respectively. Of these, Cytokeratin 19 was the most specific (specificity, 82%) in detecting porocarcinomas, and carcinoembryonic antigen was the most sensitive (sensitivity, 77%). By χ 2 test, statistically significant P values ( P = .0003). In conclusion, we found Cytokeratin 19 to be a helpful marker in the distinction of porocarcinoma from squamous cell carcinoma, although a focal staining pattern can be seen in a third of cases. The diagnostic sensitivity and specificity appear to be significantly improved using a selected panel of immunohistochemical stains that include Cytokeratin 7, Cytokeratin 19, and nestin.
-
an immunohistochemical comparison of Cytokeratin 7 Cytokeratin 15 Cytokeratin 19 cam 5 2 carcinoembryonic antigen and nestin in differentiating porocarcinoma from squamous cell carcinoma
Human Pathology, 2012Co-Authors: Meera Mahalingam, Joanna E Richards, Alona Muzikansky, Angelica M Selim, Mai P. HoangAbstract:Summary The distinction of porocarcinoma from squamous cell carcinoma is clinically relevant but can often be a diagnostic dilemma. Current markers reported to be helpful in diagnosing porocarcinoma include carcinoembryonic antigen and Cytokeratin 7; however, their expression has been demonstrated in 30% to 80% and 13% to 22% of squamous cell carcinoma cases, respectively. In this study, we assessed immunohistochemical expression of Cytokeratin 7, Cytokeratin 15, Cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in 67 cases (39 porocarcinomas and 28 moderately differentiated squamous cell carcinomas) to determine their use as histologic adjuncts. Expression of carcinoembryonic antigen, Cytokeratin 19, Cytokeratin 7, CAM 5.2, Cytokeratin 15, and nestin was seen in 77%, 67%, 64%, 51%, 49%, and 13% of porocarcinomas, respectively; and in 57%, 18%, 26%, 32%, 30%, and 37% of squamous cell carcinomas, respectively. Of these, Cytokeratin 19 was the most specific (specificity, 82%) in detecting porocarcinomas, and carcinoembryonic antigen was the most sensitive (sensitivity, 77%). By χ 2 test, statistically significant P values ( P = .0003). In conclusion, we found Cytokeratin 19 to be a helpful marker in the distinction of porocarcinoma from squamous cell carcinoma, although a focal staining pattern can be seen in a third of cases. The diagnostic sensitivity and specificity appear to be significantly improved using a selected panel of immunohistochemical stains that include Cytokeratin 7, Cytokeratin 19, and nestin.
Joanna E Richards - One of the best experts on this subject based on the ideXlab platform.
-
an immunohistochemical comparison of Cytokeratin 7 Cytokeratin 15 Cytokeratin 19 cam 5 2 carcinoembryonic antigen and nestin in differentiating porocarcinoma from squamous cell carcinoma
Human Pathology, 2012Co-Authors: Meera Mahalingam, Joanna E Richards, Alona Muzikansky, Angelica M Selim, Mai P. HoangAbstract:Summary The distinction of porocarcinoma from squamous cell carcinoma is clinically relevant but can often be a diagnostic dilemma. Current markers reported to be helpful in diagnosing porocarcinoma include carcinoembryonic antigen and Cytokeratin 7; however, their expression has been demonstrated in 30% to 80% and 13% to 22% of squamous cell carcinoma cases, respectively. In this study, we assessed immunohistochemical expression of Cytokeratin 7, Cytokeratin 15, Cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in 67 cases (39 porocarcinomas and 28 moderately differentiated squamous cell carcinomas) to determine their use as histologic adjuncts. Expression of carcinoembryonic antigen, Cytokeratin 19, Cytokeratin 7, CAM 5.2, Cytokeratin 15, and nestin was seen in 77%, 67%, 64%, 51%, 49%, and 13% of porocarcinomas, respectively; and in 57%, 18%, 26%, 32%, 30%, and 37% of squamous cell carcinomas, respectively. Of these, Cytokeratin 19 was the most specific (specificity, 82%) in detecting porocarcinomas, and carcinoembryonic antigen was the most sensitive (sensitivity, 77%). By χ 2 test, statistically significant P values ( P = .0003). In conclusion, we found Cytokeratin 19 to be a helpful marker in the distinction of porocarcinoma from squamous cell carcinoma, although a focal staining pattern can be seen in a third of cases. The diagnostic sensitivity and specificity appear to be significantly improved using a selected panel of immunohistochemical stains that include Cytokeratin 7, Cytokeratin 19, and nestin.
-
an immunohistochemical comparison of Cytokeratin 7 Cytokeratin 15 Cytokeratin 19 cam 5 2 carcinoembryonic antigen and nestin in differentiating porocarcinoma from squamous cell carcinoma
Human Pathology, 2012Co-Authors: Meera Mahalingam, Joanna E Richards, Alona Muzikansky, Angelica M Selim, Mai P. HoangAbstract:Summary The distinction of porocarcinoma from squamous cell carcinoma is clinically relevant but can often be a diagnostic dilemma. Current markers reported to be helpful in diagnosing porocarcinoma include carcinoembryonic antigen and Cytokeratin 7; however, their expression has been demonstrated in 30% to 80% and 13% to 22% of squamous cell carcinoma cases, respectively. In this study, we assessed immunohistochemical expression of Cytokeratin 7, Cytokeratin 15, Cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in 67 cases (39 porocarcinomas and 28 moderately differentiated squamous cell carcinomas) to determine their use as histologic adjuncts. Expression of carcinoembryonic antigen, Cytokeratin 19, Cytokeratin 7, CAM 5.2, Cytokeratin 15, and nestin was seen in 77%, 67%, 64%, 51%, 49%, and 13% of porocarcinomas, respectively; and in 57%, 18%, 26%, 32%, 30%, and 37% of squamous cell carcinomas, respectively. Of these, Cytokeratin 19 was the most specific (specificity, 82%) in detecting porocarcinomas, and carcinoembryonic antigen was the most sensitive (sensitivity, 77%). By χ 2 test, statistically significant P values ( P = .0003). In conclusion, we found Cytokeratin 19 to be a helpful marker in the distinction of porocarcinoma from squamous cell carcinoma, although a focal staining pattern can be seen in a third of cases. The diagnostic sensitivity and specificity appear to be significantly improved using a selected panel of immunohistochemical stains that include Cytokeratin 7, Cytokeratin 19, and nestin.
-
stem cell markers Cytokeratin 15 Cytokeratin 19 and p63 in in situ and invasive cutaneous epithelial lesions
Modern Pathology, 2011Co-Authors: Ossama Abbas, Joanna E Richards, Ron Yaar, Meera MahalingamAbstract:The inherent longetivity of stem cells causes them to be susceptible to multiple genetic hits. Thus, it is not surprising that stem cells are implicated in the etiopathogenesis of select cutaneous neoplasms. However, most studies to date are restricted to the use of a single marker (p63, Cytokeratin-15 or Cytokeratin-19) and do not appear to compare distribution of stem cell markers in a spectrum of cutaneous in situ versus invasive epithelial malignancies. In this study, we evaluate expression of Cytokeratin-15, Cytokeratin-19, and p63 in a series of primary cutaneous epithelial lesions that include actinic keratosis (n=29), squamous cell carcinoma in situ (n=30), bowenoid papulosis (n=15) and squamous cell carcinoma, well differentiated (n=29) in order to evaluate the role of stem cell marker expression in the grading and development of in situ and invasive malignancies. For Cytokeratin-15, expression was retained in actinic keratosis (38%), squamous cell carcinoma in situ (53%) and bowenoid papulosis (60%) but appeared to be lost in squamous cell carcinoma (3%) with statistically significant differences observed between groups that retained versus those that did not (P<0.05 for all three); for Cytokeratin-19, patchy yet basal expression was noted in actinic keratosis (21%), patchy and suprabasal expression was noted in squamous cell carcinoma in situ (37%), bowenoid papulosis (13%) and squamous cell carcinoma (24%) with no statistically significant differences between groups; for p63, expression was retained in actinic keratosis (90%), squamous cell carcinoma in situ (87%), bowenoid papulosis (60%) and squamous cell carcinoma (100%) with no statistically significant differences between groups. In summary, our findings expand the neoplasms which involve stem cells to include cutaneous epithelial malignancies. Differential localization of each of these markers argues in favor of stem cell heterogeneity.
Shoji Kubo - One of the best experts on this subject based on the ideXlab platform.
-
serum Cytokeratin 19 fragment cyfra21 1 as a prognostic factor in intrahepatic cholangiocarcinoma
Annals of Surgical Oncology, 2008Co-Authors: Takahiro Uenishi, Osamu Yamazaki, Hiromu Tanaka, Shigekazu Takemura, Takatsugu Yamamoto, Shogo Tanaka, Shuhei Nishiguchi, Shoji KuboAbstract:A high serum Cytokeratin 19 fragment (CYFRA21-1) concentration in patients with various cancers is associated with poor prognosis. This study aimed to establish the clinical significance of preoperative serum CYFRA21-1 in patients with intrahepatic cholangiocarcinoma. CYFRA21-1, carcinoembryonic antigen (CEA), and carbohydrate antigen (CA) 19-9 concentrations were measured in sera from 71 patients with intrahepatic cholangiocarcinoma. The prognostic significance of serum CYFRA21-1 levels was assessed by univariate and multivariate analyses. Analysis of the areas under the receiver operator characteristic (ROC) curves clearly showed better discrimination between intrahepatic cholangiocarcinoma and benign liver diseases for CYFRA 21-1 than for CEA or CA 19-9. Based on the maximization of the Youden’s index, the optimal cut-off value was 2.7 ng ml−1 for CYFRA 21-1 (sensitivity, 74.7%; specificity, 92.2%). The serum CYFRA21-1 concentration was related to tumor stage, since the CYFRA21-1 concentrations varied according to tumor size, vascular invasion, and number of tumors. The 3-year recurrence-free survival rates for patients with high and low concentrations of CYFRA21-1 were 25.0% and 76.2%, respectively (log-rank test, p < 0.01). The 3-year overall survival rates for patients with high and low concentrations of CYFRA21-1 were 39.4% and 63.6%, respectively (p = 0.01). On multivariate analysis, a high concentration of CYFRA21-1, nodal metastases, and a microscopic resection margin involvement were independent prognostic factors associated with both tumor recurrence and postoperative death. A high serum CYFRA21-1 concentration is associated with tumor progression and poor postoperative outcomes in patients with intrahepatic cholangiocarcinoma.
-
Serum Cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Annals of surgical oncology, 2007Co-Authors: Takahiro Uenishi, Osamu Yamazaki, Hiromu Tanaka, Shigekazu Takemura, Takatsugu Yamamoto, Shogo Tanaka, Shuhei Nishiguchi, Shoji KuboAbstract:Background A high serum Cytokeratin 19 fragment (CYFRA21-1) concentration in patients with various cancers is associated with poor prognosis. This study aimed to establish the clinical significance of preoperative serum CYFRA21-1 in patients with intrahepatic cholangiocarcinoma.
-
clinical significance of serum Cytokeratin 19 fragment cyfra 21 1 in hepatocellular carcinoma
Journal of Hepato-biliary-pancreatic Surgery, 2006Co-Authors: Takahiro Uenishi, Osamu Yamazaki, Hiromu Tanaka, Takatsugu Yamamoto, Shogo Tanaka, Kazuhiro Hirohashi, Seikan Hai, Koichi Ono, Shoji KuboAbstract:Background/Purpose CYFRA 21-1, a soluble fragment of Cytokeratin 19, is increased in serum in some patients with hepatocellular carcinoma, but the clinical significance of this increase is still unknown.
K Kashiwabara - One of the best experts on this subject based on the ideXlab platform.
-
prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma related antigen and Cytokeratin 19 fragment levels
Clinica Chimica Acta, 2000Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined differences in the 2-year survival rate in bronchogenic squamous cell carcinoma patients with normal serum levels of both Cytokeratin 19 fragment (CYFRA 21-1) and squamous cell carcinoma-related antigen (SCC) (NL group, n=15), patients with only increased SCC levels (SCC+ group, n=14), patients with only increased CYFRA 21-1 levels (CYFRA+ group, n=14), and patients with elevated levels of both CYFRA 21-1 and SCC (EL group, n=65). The 2-year survival rates for the CYFRA+ and the EL group were lower than those for the SCC+ group and the NL group (0 and 12.9% vs. 66.7 and 85.6%, log rank: p<0.0001, Wilcoxon: p<0.0001). However, there were no differences between the rate for the SCC+ and the NL group and between that for the CYFRA+ and the EL group. Serum carcinoembryonic antigen (CEA) levels increased in the patients with the elevated CYFRA 21-1 levels. This results suggest that there may be some differences between squamous cell carcinoma patients with increased CYFRA 21-1 levels and those with normal levels and that it is CYFRA 21-1 levels, not SCC levels, that relate to the prognosis.
-
serum Cytokeratin 19 fragment levels in non small cell lung cancer patients according to t factor in the tnm classification
Clinica Chimica Acta, 1999Co-Authors: K Kashiwabara, H Nakamura, T EsakiAbstract:We examined changes in Cytokeratin 19 fragment (CYFRA 21-1) levels in relation to the T factor in 64 non-small cell N2M0 lung cancer patients. Although a correlation between the levels and T factor was found (ρ=0.627, p<0.0001), there was no difference between the levels in T3 and T4. Serum CYFRA 21-1 levels increased in the order of the following groups: the limited tumor group (T1+T2: n=28), the group with tumor extending to the pleura or chest wall (T3: n=13), and the group with tumor invading into the mediastinum (T4: n=12). The level was lower in the group with malignant pleural effusion (T4: n=11) than in the group with tumor invading into the mediastinum (6.7±4.7 ng/ml vs. 12.2±8.1 ng/ml, p=0.0046). We suspect that the presence of malignant pleural effusion is not directly related to the three-dimensional expansion of the tumor and this is a reason why CYFRA 21-1 levels in T4 are not higher than those in T3.
-
correlation between serum Cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non malignant diseases
Clinica Chimica Acta, 1998Co-Authors: K Kashiwabara, H Nakamura, Toshio Kiguchi, Takeshi MatsuokaAbstract:It has been reported that Cytokeratin 19 fragment (CYFRA 21-1) is superior to tissue polypeptide antigen (TPA) as a tumor marker, although there is a high correlation between CYFRA 21-1 and TPA levels in patients with lung cancer. We investigated correlations between these tumor markers in patients with non-malignant diseases. Marked correlations were found between CYFRA 21-1 and TPA levels in healthy subjects (n=31), non-insulin-dependent diabetes mellitus (n=160) and hemodialysis patients (n=83) (range of r-value=0.90–0.93, P<0.0001). However in liver cirrhosis patients (n=36), only a weak correlation was found (r=0.39, P<0.0001) and there were correlations between only TPA and both aspartate aminotransferase and alanine aminotransferase levels (r2=0.48 and 0.36, P<0.0001). The elevated TPA levels in liver cirrhosis patients may be related to the decreased specificity of TPA as a tumor marker.
-
correlation between serum Cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non small cell lung cancer
Clinica Chimica Acta, 1997Co-Authors: K Kashiwabara, H Nakamura, Toshio Kiguchi, Hisanaga Yagyu, Koji Kishi, Borrong Wei, Kazuo Yoneyama, K MatsuokaAbstract:Abstract We evaluated the correlation between serum Cytokeratin 19 fragment (CYFRA 21-1) and tissue polypeptide antigen (TPA) levels in 57 non-small cell lung cancer patients. There was a significant correlation between serum CYFRA 21-1 and TPA levels for each clinical stage and TNM (T, primary tumor; N, regional lymph node involvement; M, occurrence of distant metastasis) subcategory (range of r -value=0.809–0.998, P r -value=0.856–0.998, P P
